Structural basis of Smoothened regulation by its extracellular domains

  • Nature. 2016 Jul 28;535(7613):517-522. doi: 10.1038/nature18934.
Eamon F X Byrne  #  1 Ria Sircar  #  2 Paul S Miller  1 George Hedger  3 Giovanni Luchetti  2 Sigrid Nachtergaele  2 Mark D Tully  4 Laurel Mydock-McGrane  5 Douglas F Covey  5 Robert P Rambo  4 Mark S P Sansom  3 Simon Newstead  #  3 Rajat Rohatgi  2 Christian Siebold  1
Affiliations
  • 1. Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • 2. Departments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
  • 3. Department of Biochemistry, University of Oxford, Oxford, UK.
  • 4. Diamond Light Source Ltd, Harwell Science &Innovation Campus, Didcot, UK.
  • 5. Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • # Contributed equally.
Abstract

Developmental signals of the Hedgehog (Hh) and Wnt families are transduced across the membrane by Frizzledclass G-protein-coupled receptors (GPCRs) composed of both a heptahelical transmembrane domain (TMD) and an extracellular cysteine-rich domain (CRD). How the large extracellular domains of GPCRs regulate signalling by the TMD is unknown. We present crystal structures of the Hh signal transducer and oncoprotein Smoothened, a GPCR that contains two distinct ligand-binding sites: one in its TMD and one in the CRD. The CRD is stacked a top the TMD, separated by an intervening wedge-like linker domain. Structure-guided mutations show that the interface between the CRD, linker domain and TMD stabilizes the inactive state of Smoothened. Unexpectedly, we find a Cholesterol molecule bound to Smoothened in the CRD binding site. Mutations predicted to prevent Cholesterol binding impair the ability of Smoothened to transmit native Hh signals. Binding of a clinically used antagonist, vismodegib, to the TMD induces a conformational change that is propagated to the CRD, resulting in loss of Cholesterol from the CRD-linker domain-TMD interface. Our results clarify the structural mechanism by which the activity of a GPCR is controlled by ligand-regulated interactions between its extracellular and transmembrane domains.